Other Events ·
enGene Therapeutics Inc. updated its Corporate Presentation in July 2026, highlighting the clinical progress of its…
ENGNWenGene Therapeutics Inc.
enGene Therapeutics Inc. updated its Corporate Presentation in July 2026, highlighting the clinical progress of its lead program, detalimogene, for non-muscle-invasive bladder cancer (NMIBC). The company expects to file a Biologics License Application (BLA) and provide 12-month data updates from the 125-patient pivotal LEGEND study Cohort 1, pivotal cohort 12-month data update and BLA filing expected in 2H 2026, and potential approval and platform designation in 2027. The company reports having $285M in cash to support these milestones. enGene Therapeutics Inc. is a biotechnology company focused on developing non-viral genetic medicines.